Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Adherence | 27 | 2025 | 330 | 7.510 |
Why?
|
| Medicare Part C | 12 | 2025 | 34 | 5.490 |
Why?
|
| Motivational Interviewing | 8 | 2025 | 50 | 4.720 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2025 | 734 | 4.220 |
Why?
|
| Drug Monitoring | 10 | 2024 | 274 | 3.910 |
Why?
|
| Hypertension | 13 | 2025 | 1302 | 3.730 |
Why?
|
| Hyperlipidemias | 5 | 2022 | 181 | 3.180 |
Why?
|
| Diabetes Mellitus | 10 | 2025 | 865 | 2.640 |
Why?
|
| Atrial Fibrillation | 6 | 2025 | 711 | 2.610 |
Why?
|
| Smoking Cessation | 7 | 2016 | 184 | 2.580 |
Why?
|
| Antihypertensive Agents | 6 | 2025 | 400 | 2.540 |
Why?
|
| Anticoagulants | 5 | 2025 | 581 | 2.400 |
Why?
|
| Hypoglycemic Agents | 5 | 2025 | 440 | 2.340 |
Why?
|
| Smoking | 8 | 2016 | 904 | 1.820 |
Why?
|
| Angiotensin Receptor Antagonists | 7 | 2025 | 131 | 1.760 |
Why?
|
| Aged | 50 | 2025 | 20431 | 1.750 |
Why?
|
| United States | 42 | 2025 | 11386 | 1.740 |
Why?
|
| Medicare | 15 | 2025 | 424 | 1.690 |
Why?
|
| Retrospective Studies | 50 | 2025 | 17065 | 1.590 |
Why?
|
| Medicare Part D | 2 | 2021 | 12 | 1.350 |
Why?
|
| Antipsychotic Agents | 8 | 2025 | 373 | 1.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2025 | 1340 | 1.300 |
Why?
|
| Cardiovascular Diseases | 8 | 2025 | 2036 | 1.290 |
Why?
|
| Administration, Oral | 9 | 2025 | 681 | 1.180 |
Why?
|
| Pharmaceutical Services | 3 | 2021 | 35 | 1.170 |
Why?
|
| Breast Neoplasms | 13 | 2025 | 2586 | 1.150 |
Why?
|
| Drug Therapy, Combination | 8 | 2025 | 1140 | 1.080 |
Why?
|
| Rivaroxaban | 2 | 2024 | 48 | 1.060 |
Why?
|
| Stroke | 3 | 2025 | 1028 | 1.050 |
Why?
|
| Factor Xa Inhibitors | 2 | 2024 | 58 | 1.040 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 6695 | 1.020 |
Why?
|
| Markov Chains | 2 | 2024 | 95 | 1.010 |
Why?
|
| Weight Gain | 5 | 2025 | 377 | 1.000 |
Why?
|
| Pyridones | 2 | 2024 | 137 | 1.000 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 123 | 0.990 |
Why?
|
| Humans | 88 | 2025 | 127099 | 0.980 |
Why?
|
| Varenicline | 2 | 2016 | 12 | 0.970 |
Why?
|
| Bupropion | 2 | 2016 | 26 | 0.960 |
Why?
|
| Multiple Myeloma | 2 | 2025 | 208 | 0.930 |
Why?
|
| Female | 64 | 2025 | 68483 | 0.920 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2023 | 211 | 0.900 |
Why?
|
| Pyrazoles | 2 | 2024 | 330 | 0.890 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 534 | 0.860 |
Why?
|
| Male | 52 | 2025 | 62658 | 0.860 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 100 | 0.850 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2021 | 16 | 0.850 |
Why?
|
| Hemorrhage | 2 | 2025 | 492 | 0.830 |
Why?
|
| Middle Aged | 34 | 2025 | 27801 | 0.810 |
Why?
|
| Obesity | 6 | 2023 | 2320 | 0.800 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2019 | 754 | 0.790 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 1238 | 0.770 |
Why?
|
| Texas | 15 | 2025 | 3563 | 0.760 |
Why?
|
| Warfarin | 2 | 2022 | 122 | 0.730 |
Why?
|
| Students | 3 | 2013 | 248 | 0.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1309 | 0.710 |
Why?
|
| Logistic Models | 11 | 2021 | 1788 | 0.700 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2025 | 253 | 0.690 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 778 | 0.650 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2024 | 83 | 0.630 |
Why?
|
| Students, Pharmacy | 2 | 2019 | 81 | 0.620 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 81 | 0.610 |
Why?
|
| Benchmarking | 1 | 2020 | 132 | 0.610 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 152 | 0.600 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 93 | 0.570 |
Why?
|
| Medicaid | 4 | 2025 | 242 | 0.570 |
Why?
|
| Social Class | 4 | 2025 | 206 | 0.570 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 227 | 0.570 |
Why?
|
| Cancer Survivors | 2 | 2018 | 258 | 0.550 |
Why?
|
| Adult | 33 | 2025 | 30435 | 0.540 |
Why?
|
| Buprenorphine | 3 | 2025 | 107 | 0.540 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 319 | 0.530 |
Why?
|
| Hospitalization | 3 | 2020 | 1879 | 0.520 |
Why?
|
| Health Care Costs | 1 | 2020 | 391 | 0.510 |
Why?
|
| Cross-Sectional Studies | 15 | 2025 | 3680 | 0.500 |
Why?
|
| Patient Readmission | 1 | 2020 | 413 | 0.490 |
Why?
|
| Drug Combinations | 4 | 2020 | 270 | 0.490 |
Why?
|
| Arabs | 1 | 2015 | 29 | 0.480 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 80 | 0.480 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 32 | 0.480 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 35 | 0.470 |
Why?
|
| Universities | 3 | 2013 | 120 | 0.460 |
Why?
|
| Tobacco Products | 1 | 2015 | 60 | 0.460 |
Why?
|
| Opioid-Related Disorders | 3 | 2025 | 287 | 0.460 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 89 | 0.460 |
Why?
|
| Blood Glucose | 5 | 2025 | 968 | 0.450 |
Why?
|
| Telephone | 4 | 2025 | 112 | 0.450 |
Why?
|
| Primary Health Care | 1 | 2021 | 778 | 0.440 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 152 | 0.440 |
Why?
|
| Young Adult | 14 | 2025 | 9694 | 0.440 |
Why?
|
| Schizophrenia | 1 | 2016 | 320 | 0.410 |
Why?
|
| Health Behavior | 1 | 2015 | 386 | 0.380 |
Why?
|
| Pharmacists | 3 | 2020 | 102 | 0.380 |
Why?
|
| Social Perception | 1 | 2013 | 53 | 0.380 |
Why?
|
| Risk-Taking | 2 | 2012 | 97 | 0.370 |
Why?
|
| Nicotine | 1 | 2013 | 112 | 0.370 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2016 | 8 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2025 | 576 | 0.340 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 490 | 0.320 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2025 | 62 | 0.320 |
Why?
|
| Opiate Substitution Treatment | 3 | 2025 | 38 | 0.310 |
Why?
|
| Adolescent | 17 | 2025 | 20082 | 0.300 |
Why?
|
| Physicians | 4 | 2019 | 623 | 0.300 |
Why?
|
| Body Mass Index | 7 | 2025 | 1651 | 0.290 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 483 | 0.290 |
Why?
|
| Disease Management | 1 | 2012 | 544 | 0.290 |
Why?
|
| Patient Compliance | 2 | 2015 | 462 | 0.280 |
Why?
|
| Hydrocodone | 2 | 2019 | 36 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2025 | 48 | 0.270 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2024 | 25 | 0.270 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 835 | 0.250 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 1369 | 0.250 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 457 | 0.240 |
Why?
|
| Polypharmacy | 1 | 2005 | 35 | 0.240 |
Why?
|
| Health Expenditures | 2 | 2024 | 132 | 0.230 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5148 | 0.230 |
Why?
|
| Proteasome Inhibitors | 1 | 2025 | 57 | 0.230 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 661 | 0.230 |
Why?
|
| Risk Factors | 8 | 2024 | 10610 | 0.220 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 18 | 0.220 |
Why?
|
| Aromatase Inhibitors | 3 | 2020 | 78 | 0.220 |
Why?
|
| Central Nervous System Stimulants | 1 | 2025 | 125 | 0.210 |
Why?
|
| Dabigatran | 1 | 2024 | 26 | 0.210 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 110 | 0.210 |
Why?
|
| Thalidomide | 1 | 2024 | 36 | 0.210 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1431 | 0.210 |
Why?
|
| Delirium | 1 | 2024 | 66 | 0.200 |
Why?
|
| Confidence Intervals | 3 | 2013 | 267 | 0.200 |
Why?
|
| Ambulatory Care | 2 | 2020 | 398 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 130 | 0.200 |
Why?
|
| Hypolipidemic Agents | 1 | 2004 | 183 | 0.190 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2022 | 10 | 0.190 |
Why?
|
| Databases, Factual | 2 | 2024 | 1194 | 0.190 |
Why?
|
| Antidepressive Agents | 1 | 2025 | 316 | 0.190 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2022 | 46 | 0.190 |
Why?
|
| Machine Learning | 1 | 2025 | 325 | 0.180 |
Why?
|
| Cognition Disorders | 1 | 2005 | 542 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 1054 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2024 | 267 | 0.170 |
Why?
|
| Pharmacies | 1 | 2021 | 15 | 0.170 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 114 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 18 | 0.170 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 3933 | 0.170 |
Why?
|
| Health Surveys | 2 | 2012 | 255 | 0.170 |
Why?
|
| Tamoxifen | 2 | 2020 | 345 | 0.170 |
Why?
|
| Odds Ratio | 3 | 2013 | 1216 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2024 | 659 | 0.170 |
Why?
|
| Comorbidity | 2 | 2016 | 1562 | 0.170 |
Why?
|
| HIV Infections | 3 | 2023 | 1954 | 0.170 |
Why?
|
| Diabetes Complications | 1 | 2022 | 193 | 0.170 |
Why?
|
| Metformin | 1 | 2022 | 154 | 0.170 |
Why?
|
| Controlled Substances | 2 | 2019 | 11 | 0.160 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 17 | 0.160 |
Why?
|
| Neomycin | 1 | 2020 | 36 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2025 | 6242 | 0.160 |
Why?
|
| Lactulose | 1 | 2020 | 27 | 0.160 |
Why?
|
| Sex Factors | 2 | 2019 | 1311 | 0.160 |
Why?
|
| Sexual Behavior | 2 | 2013 | 245 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 59 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2022 | 887 | 0.160 |
Why?
|
| Acute Pain | 1 | 2019 | 17 | 0.150 |
Why?
|
| Forecasting | 1 | 2021 | 358 | 0.150 |
Why?
|
| Military Personnel | 2 | 2013 | 208 | 0.150 |
Why?
|
| Psychological Theory | 2 | 2016 | 35 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2025 | 12567 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 345 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 486 | 0.150 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 603 | 0.140 |
Why?
|
| Intention | 2 | 2016 | 100 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 204 | 0.140 |
Why?
|
| Health Services | 1 | 2018 | 66 | 0.140 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 231 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1387 | 0.140 |
Why?
|
| Quinolines | 1 | 2019 | 112 | 0.140 |
Why?
|
| Standard of Care | 1 | 2018 | 133 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2019 | 283 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2019 | 438 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 168 | 0.130 |
Why?
|
| Age Factors | 2 | 2019 | 2799 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2022 | 642 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 291 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2021 | 1199 | 0.130 |
Why?
|
| Chronic Pain | 1 | 2019 | 154 | 0.130 |
Why?
|
| Perception | 2 | 2022 | 228 | 0.130 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 184 | 0.130 |
Why?
|
| Middle East | 2 | 2016 | 36 | 0.130 |
Why?
|
| Child | 10 | 2025 | 25228 | 0.120 |
Why?
|
| Smoking Prevention | 1 | 2016 | 33 | 0.120 |
Why?
|
| Recurrence | 1 | 2020 | 1421 | 0.120 |
Why?
|
| Depression | 1 | 2025 | 1294 | 0.120 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 22 | 0.120 |
Why?
|
| Health Planning Guidelines | 1 | 2016 | 33 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2023 | 862 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2020 | 1399 | 0.120 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 66 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 687 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 429 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2018 | 4972 | 0.110 |
Why?
|
| Cholinergic Antagonists | 2 | 2024 | 47 | 0.100 |
Why?
|
| Socioeconomic Factors | 3 | 2025 | 881 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 735 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2019 | 1309 | 0.100 |
Why?
|
| Propylene Glycol | 1 | 2013 | 7 | 0.100 |
Why?
|
| Social Values | 1 | 2013 | 46 | 0.100 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2013 | 58 | 0.100 |
Why?
|
| Pakistan | 1 | 2012 | 91 | 0.090 |
Why?
|
| Jordan | 1 | 2012 | 9 | 0.090 |
Why?
|
| India | 1 | 2012 | 228 | 0.090 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 98 | 0.090 |
Why?
|
| Focus Groups | 1 | 2013 | 216 | 0.090 |
Why?
|
| Sunlight | 1 | 2011 | 27 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 398 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 630 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 369 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 370 | 0.090 |
Why?
|
| Health Personnel | 1 | 2016 | 535 | 0.080 |
Why?
|
| Self Report | 1 | 2014 | 538 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 73 | 0.080 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 124 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2025 | 798 | 0.080 |
Why?
|
| Cholesterol | 2 | 2023 | 536 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 180 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2025 | 714 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 270 | 0.080 |
Why?
|
| Receptors, Progesterone | 2 | 2025 | 663 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2519 | 0.070 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 16 | 0.070 |
Why?
|
| Incidence | 1 | 2015 | 3259 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 384 | 0.070 |
Why?
|
| Electronic Health Records | 2 | 2025 | 781 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3322 | 0.060 |
Why?
|
| Purines | 1 | 2025 | 110 | 0.060 |
Why?
|
| New England | 1 | 2004 | 11 | 0.060 |
Why?
|
| Aminopyridines | 1 | 2025 | 61 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2005 | 163 | 0.060 |
Why?
|
| Child Psychiatry | 1 | 2024 | 16 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2025 | 147 | 0.050 |
Why?
|
| Aripiprazole | 1 | 2024 | 23 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 729 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 765 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2004 | 77 | 0.050 |
Why?
|
| Pyridines | 1 | 2025 | 251 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 64 | 0.050 |
Why?
|
| Piperazines | 1 | 2025 | 256 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2005 | 285 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2024 | 182 | 0.050 |
Why?
|
| Mortality | 1 | 2004 | 254 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 424 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2022 | 56 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 382 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2025 | 456 | 0.050 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 40 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 96 | 0.050 |
Why?
|
| Nigeria | 2 | 2013 | 69 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 193 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 141 | 0.040 |
Why?
|
| Sexual Partners | 2 | 2013 | 79 | 0.040 |
Why?
|
| Neoplasms | 1 | 2016 | 2856 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 256 | 0.040 |
Why?
|
| Research | 1 | 2023 | 256 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2004 | 640 | 0.040 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 695 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 74 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 151 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 546 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 206 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 120 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 785 | 0.040 |
Why?
|
| Survival Rate | 1 | 2023 | 2111 | 0.030 |
Why?
|
| United States Government Agencies | 1 | 2016 | 5 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1291 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1140 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 139 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 48 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 132 | 0.030 |
Why?
|
| Mammography | 1 | 2015 | 129 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 201 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2013 | 41 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 269 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 317 | 0.020 |
Why?
|
| Communication | 1 | 2016 | 512 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 92 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 1537 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 50 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 198 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 14423 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 2612 | 0.010 |
Why?
|
| Heart Failure | 1 | 2016 | 2288 | 0.010 |
Why?
|